CNS Drugs

, Volume 27, Issue 8, pp 653–662 | Cite as

Buprenorphine Use in Pregnant Opioid Users: A Critical Review

  • Michael SoykaEmail author
Review Article


Pregnancy in opioid users poses a number of problems to treating physicians. Most guidelines recommend maintenance treatment to manage opioid addiction in pregnancy, with methadone being the gold standard. More recently, buprenorphine has been discussed as an alternate medication. The use and efficacy of buprenorphine in pregnancy is still controversial. This article reviews the current database on the basis of a detailed and critical literature search performed in MEDLINE (206 counts). Most of the relevant studies (randomised clinical trials and one national cohort sample) were published in the last 2 years and mainly compared buprenorphine with methadone. Some studies are related to maternal outcomes, others to foetal, neonatal or older child outcomes. With respect to maternal outcomes, most studies suggest that buprenorphine has similar effects to methadone. Very few data from small studies discuss an effect of buprenorphine on neurodevelopment of the foetus. Neonatal abstinence syndrome is common in infants of both buprenorphine- and methadone-maintained mothers. As regards neonatal outcomes, buprenorphine has the same clinical outcome as methadone, although some newer studies suggest that it causes fewer withdrawal symptoms. Since hardly any studies have investigated the combination of buprenorphine with naloxone (which has been suggested to possibly have teratogenic effects) in pregnant women, a switch to buprenorphine monotherapy is recommended in women who become pregnant while receiving the combination product. These novel findings indicate that buprenorphine is emerging as a first-line treatment for pregnant opioid users.


Naloxone Buprenorphine Neonatal Outcome Methadone Maintenance Treatment Opioid Dependence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No funding was used to prepare this review.

Conflict of interest

For the past 5 years, the author has worked as a consultant or has received research grants from Sanofi, Cephalopharm, Phoenux, Reckitt Benckiser, Prempharm and Lundbeck.


The author thanks Jacquie Klesing, ELS, for editing assistance with the manuscript.


  1. 1.
    Soyka M, Kranzler HR, van den Brink W, Krystal J, Moller HJ, Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: opioid dependence. World J Biol Psychiatry. 2011;12(3):160–87. doi: 10.3109/15622975.2011.561872.PubMedCrossRefGoogle Scholar
  2. 2.
    Davids E, Gastpar M. Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol. 2004;14(3):209–16. doi: 10.1016/S0924-977X(03)00146-9.PubMedCrossRefGoogle Scholar
  3. 3.
    Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009;69(5):577–607. doi: 10.2165/00003495-200969050-00006.PubMedCrossRefGoogle Scholar
  4. 4.
    Preston KL, Bigelow GE, Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend. 1990;25(1):27–34 pii: 0376-8716(90)90136-3.PubMedCrossRefGoogle Scholar
  5. 5.
    Kleber HD, Weiss RD, Anton RF Jr, George TP, Greenfield SF, Kosten TR, et al. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007;164(4 Suppl):5–123.PubMedGoogle Scholar
  6. 6.
    Mammen K, Bell J. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother. 2009;10(15):2537–44. doi: 10.1517/14656560903213405.PubMedCrossRefGoogle Scholar
  7. 7.
    Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54(8):713–20 (A).Google Scholar
  8. 8.
    Kakko J, Gronbladh L, Svanborg KD, von Wachenfeldt J, Ruck C, Rawlings B, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164(5):797–803. doi: 10.1176/appi.ajp.164.5.797.PubMedCrossRefGoogle Scholar
  9. 9.
    Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry. 2008;9(1):6–23. doi: 10.1080/15622970801896390.PubMedCrossRefGoogle Scholar
  10. 10.
    ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012;119(5):1070–6. doi: 10.1097/AOG.0b013e318256496e.Google Scholar
  11. 11.
    Minozzi S, Amato L, Vecchi S, Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev. 2008;(2):CD006318. doi: 10.1002/14651858.CD006318.pub2.
  12. 12.
    Black KI, Stephens C, Haber PS, Lintzeris N. Unplanned pregnancy and contraceptive use in women attending drug treatment services. Aust N Z J Obstet Gynaecol. 2012;52(2):146–50. doi: 10.1111/j.1479-828X.2012.01413.x.PubMedCrossRefGoogle Scholar
  13. 13.
    Armstrong KA, Kennedy MG, Kline A, Tunstall C. Reproductive health needs: comparing women at high, drug-related risk of HIV with a national sample. J Am Med Womens Assoc. 1999;54(2):65–70, 8.Google Scholar
  14. 14.
    Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G, et al. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. 2011;40(2):199–202. doi: 10.1016/j.jsat.2010.08.011.PubMedCrossRefGoogle Scholar
  15. 15.
    Mactier H. The management of heroin misuse in pregnancy: time for a rethink? Arch Dis Child Fetal Neonatal Ed. 2011;96(6):F457–60. doi: 10.1136/adc.2009.181057.PubMedCrossRefGoogle Scholar
  16. 16.
    European Monitoring Centre for Drugs and Drug Addiction. Drug users and their children: from risks in pregnancy to targeted responses for families, a European snapshot. EMCDDA Research Monograph. Lisbon: EMCDDA; 2012.Google Scholar
  17. 17.
    Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003;70(2 Suppl):S87–101.PubMedCrossRefGoogle Scholar
  18. 18.
    Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96(1–2):69–78. doi: 10.1016/j.drugalcdep.2008.01.025.PubMedCrossRefGoogle Scholar
  19. 19.
    Meyer M, Benvenuto A, Howard D, Johnston A, Plante D, Metayer J, et al. Development of a substance abuse program for opioid-dependent nonurban pregnant women improves outcome. J Addict Med. 2012;6(2):124–30. doi: 10.1097/ADM.0b013e3182541933.PubMedCrossRefGoogle Scholar
  20. 20.
    Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. 2004.Google Scholar
  21. 21.
    American Society of Addiction Medicine. Policy statement on women, alcohol and other drugs, and pregnancy. 2011.Google Scholar
  22. 22.
    Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat. 2008;35(3):245–59. doi: 10.1016/j.jsat.2007.10.007.PubMedCrossRefGoogle Scholar
  23. 23.
    Zuspan FP, Gumpel JA, Mejia-Zelaya A, Madden J, Davis R. Fetal stress from methadone withdrawal. Am J Obstet Gynecol. 1975;122(1):43–6.PubMedGoogle Scholar
  24. 24.
    Wong S, Ordean A, Kahan M. Substance use in pregnancy. J Obstet Gynaecol Can. 2011;33(4):367–84.PubMedGoogle Scholar
  25. 25.
    Lingford-Hughes AR, Welch S, Peters L, Nutt DJ. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol. 2012;26(7):899–952. doi: 10.1177/0269881112444324.PubMedCrossRefGoogle Scholar
  26. 26.
    Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012;72(6):747–57. doi: 10.2165/11632820-000000000-00000.PubMedCrossRefGoogle Scholar
  27. 27.
    Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol. 2008;6(2):125–50. doi: 10.2174/157015908784533842.PubMedCrossRefGoogle Scholar
  28. 28.
    Jones HE, Johnson RE, Jasinski DR, Milio L. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend. 2005;78(1):33–8. doi: 10.1016/j.drugalcdep.2004.08.027.PubMedCrossRefGoogle Scholar
  29. 29.
    Jones HE, Johnson RE, Jasinski DR, O‘Grady KE, Chisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1):1–10. doi: 10.1016/j.drugalcdep.2004.11.013.PubMedCrossRefGoogle Scholar
  30. 30.
    McCance-Katz EF. Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women. Life Sci. 2011;88(21–22):953–8. doi: 10.1016/j.lfs.2010.09.016.PubMedCrossRefGoogle Scholar
  31. 31.
    Fischer G. Treatment of opioid dependence in pregnant women. Addiction. 2000;95(8):1141–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Fischer G, Etzersdorfer P, Eder H, Jagsch R, Langer M, Weninger M. Buprenorphine maintenance in pregnant opiate addicts. Eur Addict Res. 1998;4(Suppl 1):32–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction. 2000;95(2):239–44.PubMedCrossRefGoogle Scholar
  34. 34.
    Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, Jansson LM, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 2001;63(1):97–103.PubMedCrossRefGoogle Scholar
  35. 35.
    Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction. 2004;99(2):209–14.PubMedCrossRefGoogle Scholar
  36. 36.
    Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend. 2006;82(3):250–7. doi: 10.1016/j.drugalcdep.2005.10.001.PubMedCrossRefGoogle Scholar
  37. 37.
    McCarthy JJ. Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neona. 2012;25(2):109–12. doi: 10.3109/14767058.2011.600371.CrossRefGoogle Scholar
  38. 38.
    Schindler SD, Eder H, Ortner R, Rohrmeister K, Langer M, Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction. 2003;98(1):103–10.PubMedCrossRefGoogle Scholar
  39. 39.
    Deshmukh SV, Nanovskaya TN, Ahmed MS. Aromatase is the major enzyme metabolizing buprenorphine in human placenta. J Pharmacol Exp Ther. 2003;306(3):1099–105. doi: 10.1124/jpet.103.053199.PubMedCrossRefGoogle Scholar
  40. 40.
    Nanovskaya T, Deshmukh S, Brooks M, Ahmed MS. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther. 2002;300(1):26–33.PubMedCrossRefGoogle Scholar
  41. 41.
    Gordon AL, Lopatko OV, Somogyi AA, Foster DJ, White JM. (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. Br J Clin Pharmacol. 2010;70(6):895–902. doi: 10.1111/j.1365-2125.2010.03759.x.PubMedCrossRefGoogle Scholar
  42. 42.
    Bartu AE, Ilett KF, Hackett LP, Doherty DA, Hamilton D. Buprenorphine exposure in infants of opioid-dependent mothers at birth. Aust N Z J Obstet Gynaecol. 2012;52(4):342–7. doi: 10.1111/j.1479-828X.2012.01424.x.PubMedCrossRefGoogle Scholar
  43. 43.
    Concheiro M, Jones HE, Johnson RE, Choo R, Shakleya DM, Huestis MA. Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes. Ther Drug Monit. 2010;32(2):206–15. doi: 10.1097/FTD.0b013e3181d0bd68.PubMedGoogle Scholar
  44. 44.
    Concheiro M, Jones HE, Johnson RE, Choo R, Shakleya DM, Huestis MA. Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose and neonatal outcomes. J Anal Toxicol. 2010;34(8):498–505.PubMedCrossRefGoogle Scholar
  45. 45.
    Jansson LM, Dipietro JA, Velez M, Elko A, Williams E, Milio L, et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol. 2011;33(2):240–3. doi: 10.1016/ Scholar
  46. 46.
    Vert P, Hamon I, Hubert C, Legagneur M, Hascoet JM. [Infants of drug-addicted mothers: pitfalls of replacement therapy]. Bull Acad Natl Med. 2008;192(5):961–9; discussion 9.Google Scholar
  47. 47.
    Konijnenberg C, Melinder A. Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development. Child Neuropsychol. 2011;17(5):495–519. doi: 10.1080/09297049.2011.553591.PubMedCrossRefGoogle Scholar
  48. 48.
    Sanchez ES, Bigbee JW, Fobbs W, Robinson SE, Sato-Bigbee C. Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain. Glia. 2008;56(9):1017–27. doi: 10.1002/glia.20675.PubMedCrossRefGoogle Scholar
  49. 49.
    Eschenroeder AC, Vestal-Laborde AA, Sanchez ES, Robinson SE, Sato-Bigbee C. Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of mu-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancy. Glia. 2012;60(1):125–36. doi: 10.1002/glia.21253.PubMedCrossRefGoogle Scholar
  50. 50.
    Whitham JN, Spurrier NJ, Sawyer MG, Baghurst PA, Taplin JE, White JM, et al. The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicol Teratol. 2010;32(2):280–8. doi: 10.1016/ Scholar
  51. 51.
    Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101(2):275–81. doi: 10.1111/j.1360-0443.2006.01321.x.PubMedCrossRefGoogle Scholar
  52. 52.
    Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320–31. doi: 10.1056/NEJMoa1005359.PubMedCrossRefGoogle Scholar
  53. 53.
    Cleary BJ, Donnelly J, Strawbridge J, Gallagher PJ, Fahey T, Clarke M, et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction. 2010;105(12):2071–84. doi: 10.1111/j.1360-0443.2010.03120.x.PubMedCrossRefGoogle Scholar
  54. 54.
    Seligman NS, Salva N, Hayes EJ, Dysart KC, Pequignot EC, Baxter JK. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol. 2008;199(4):396 e1-7. doi: 10.1016/j.ajog.2008.06.088.Google Scholar
  55. 55.
    Bio LL, Siu A, Poon CY. Update on the pharmacologic management of neonatal abstinence syndrome. J Perinatol. 2011;31(11):692–701. doi: 10.1038/jp.2011.116.PubMedCrossRefGoogle Scholar
  56. 56.
    Hytinantti T, Kahila H, Renlund M, Jarvenpaa AL, Halmesmaki E, Kivitie-Kallio S. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr. 2008;97(8):1040–4. doi: 10.1111/j.1651-2227.2008.00838.x.PubMedCrossRefGoogle Scholar
  57. 57.
    Kahila H, Stefanovic V, Loukovaara M, Alfthan H, Hamalainen E, Halmesmaki E. Prenatal buprenorphine exposure: effects on biochemical markers of hypoxia and early neonatal outcome. Acta Obstet Gynecol Scand. 2008;87(11):1213–9. doi: 10.1080/00016340802460297.PubMedCrossRefGoogle Scholar
  58. 58.
    Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011;67(10):1053–9. doi: 10.1007/s00228-011-1049-9.PubMedCrossRefGoogle Scholar
  59. 59.
    Binder T, Vavrinkova B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett. 2008;29(1):80–6.PubMedGoogle Scholar
  60. 60.
    Brulet C, Chanal C, Ravel P, Mazurier E, Boulot P, Faucherre V. Multidisciplinary monitoring and psychosocial support reduce complications of opiate dependence in pregnant women: 114 pregnancies. Presse Med. 2007;36(11 Pt 1):1571–80. doi: 10.1016/j.lpm.2007.05.017.PubMedCrossRefGoogle Scholar
  61. 61.
    Newman RG, Gevertz SG. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. J Addict Dis. 2011;30(4):318–22. doi: 10.1080/10550887.2011.609806.PubMedCrossRefGoogle Scholar
  62. 62.
    Salisbury AL, Coyle MG, O‘Grady KE, Heil SH, Martin PR, Stine SM, et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction. 2012;107(Suppl 1):36–44. doi: 10.1111/j.1360-0443.2012.04037.x.PubMedCrossRefGoogle Scholar
  63. 63.
    Coyle MG, Salisbury AL, Lester BM, Jones HE, Lin H, Graf-Rohrmeister K, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction. 2012;107(Suppl 1):63–73. doi: 10.1111/j.1360-0443.2012.04040.x.PubMedCrossRefGoogle Scholar
  64. 64.
    Blandthorn J, Forster DA, Love V. Neonatal and maternal outcomes following maternal use of buprenorphine or methadone during pregnancy: findings of a retrospective audit. Women Birth. 2011;24(1):32–9. doi: 10.1016/j.wombi.2010.07.001.PubMedCrossRefGoogle Scholar
  65. 65.
    Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction. 2011;106(3):574–80. doi: 10.1111/j.1360-0443.2010.03170.x.PubMedCrossRefGoogle Scholar
  66. 66.
    Simmat-Durand L, Lejeune C, Gourarier L. Pregnancy under high-dose buprenorphine. Eur J Obstet Gynecol Reprod Biol. 2009;142(2):119–23. doi: 10.1016/j.ejogrb.2008.10.012.PubMedCrossRefGoogle Scholar
  67. 67.
    Welle-Strand GK, Skurtveit S, Jones HE, Waal H, Bakstad B, Bjarko L, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. Drug Alcohol Depend. 2013;127(1–3):200–6. doi: 10.1016/j.drugalcdep.2012.07.001.PubMedCrossRefGoogle Scholar
  68. 68.
    Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res. 2009;15(3):128–34. doi: 10.1159/000210042.PubMedCrossRefGoogle Scholar
  69. 69.
    Unger A, Jagsch R, Jones H, Arria A, Leitich H, Rohrmeister K, et al. Randomized controlled trials in pregnancy: scientific and ethical aspects Exposure to different opioid medications during pregnancy in an intra-individual comparison. Addiction. 2011;106(7):1355–62. doi: 10.1111/j.1360-0443.2011.03440.x.PubMedCrossRefGoogle Scholar
  70. 70.
    O‘Connor A, Alto W, Musgrave K, Gibbons D, Llanto L, Holden S, et al. Observational study of buprenorphine treatment of opioid-dependent pregnant women in a family medicine residency: reports on maternal and infant outcomes. J Am Board Fam Med. 2011;24(2):194–201. doi: 10.3122/jabfm.2011.02.100155.PubMedCrossRefGoogle Scholar
  71. 71.
    Jansson LM. ABM clinical protocol #21: guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med. 2009;4(4):225–8. doi: 10.1089/bfm.2009.9987.PubMedCrossRefGoogle Scholar
  72. 72.
    Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012;107(Suppl 1):5–27. doi: 10.1111/j.1360-0443.2012.04035.x.PubMedCrossRefGoogle Scholar
  73. 73.
    Park EM, Meltzer-Brody S, Suzuki J. Evaluation and management of opioid dependence in pregnancy. Psychosomatics. 2012;53(5):424–32. doi: 10.1016/j.psym.2012.04.003.PubMedCrossRefGoogle Scholar
  74. 74.
    Concheiro M, Jones HE, Johnson RE, Choo R, Huestis MA. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women. Ther Drug Monit. 2011;33(5):619–26. doi: 10.1097/FTD.0b013e318228bb2a.PubMedGoogle Scholar
  75. 75.
    Lindemalm S, Nydert P, Svensson JO, Stahle L, Sarman I. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact. 2009;25(2):199–205. doi: 10.1177/0890334408328295.PubMedCrossRefGoogle Scholar
  76. 76.
    Ilett KF, Hackett LP, Gower S, Doherty DA, Hamilton D, Bartu AE. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeed Med. 2012;7:269–74. doi: 10.1089/bfm.2011.0096.PubMedCrossRefGoogle Scholar
  77. 77.
    van Dorp E, Yassen A, Dahan A. Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf. 2007;6(2):125–32. doi: 10.1517/14740338.6.2.125.PubMedCrossRefGoogle Scholar
  78. 78.
    van Vonderen JJ, Siew ML, Hooper SB, de Boer MA, Walther FJ, te Pas AB. Effects of naloxone on the breathing pattern of a newborn exposed to maternal opiates. Acta Paediatr. 2012;101(7):e309–12. doi: 10.1111/j.1651-2227.2012.02649.x.PubMedCrossRefGoogle Scholar
  79. 79.
    Center for Substance Abuse Treatment (U.S.). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. DHHS publication. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.Google Scholar
  80. 80.
    Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? Birth Defects Res A Clin Mol Teratol. 2003;67:133–40.Google Scholar
  81. 81.
    Lund I, Fischer G, Welle-Strand GK, O’Grady KE, Debelak K, Morrone WR, Jones HE. A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse. 2013;7:61–74.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Psychiatric HospitalUniversity of MunichMunichGermany
  2. 2.Private Hospital MeiringenMeiringenSwitzerland

Personalised recommendations